argenex (NASDAQ:ARGX) Issues Quarterly Earnings Results, Beats Expectations By $1.46 EPS

argenex (NASDAQ:ARGX) announced its earnings results on Tuesday. The company reported $7.32 earnings per share for the quarter, beating the consensus estimate of $5.86 by $1.46, Zacks reports. The firm had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion. argenex had a return on equity of 44.37% and a net margin of 31.31%.

argenex Price Performance

Shares of NASDAQ:ARGX traded up $56.13 on Thursday, reaching $907.86. 428,578 shares of the company traded hands, compared to its average volume of 353,427. argenex has a fifty-two week low of $577.04 and a fifty-two week high of $953.58. The company’s 50 day moving average is $863.85 and its 200-day moving average is $813.80. The stock has a market capitalization of $56.80 billion, a PE ratio of 40.49, a P/E/G ratio of 1.08 and a beta of 0.45.

Hedge Funds Weigh In On argenex

A number of institutional investors have recently bought and sold shares of ARGX. AQR Capital Management LLC raised its holdings in shares of argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after acquiring an additional 122 shares during the period. NewEdge Advisors LLC grew its position in argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after purchasing an additional 1,431 shares in the last quarter. Focus Partners Wealth grew its position in argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after purchasing an additional 73 shares in the last quarter. Geneos Wealth Management Inc. raised its stake in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares during the period. Finally, Northwestern Mutual Wealth Management Co. raised its stake in argenex by 60.2% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after purchasing an additional 50 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Bank of America increased their price objective on shares of argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a report on Thursday, July 2nd. Weiss Ratings upgraded argenex from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, July 6th. Morgan Stanley increased their price target on argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a research note on Wednesday, June 24th. HC Wainwright reiterated a “buy” rating and set a $940.00 price target on shares of argenex in a research report on Thursday, June 25th. Finally, Guggenheim upped their price objective on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,042.67.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported second-quarter 2026 earnings that beat expectations, with EPS of $7.32 versus consensus of $5.86 and revenue of $1.54 billion versus estimates of $1.45 billion, reinforcing solid execution. Article Title
• Positive Sentiment: Management said Vyvgart sales jumped about 60% year over year, a key growth driver that supports the company’s near-term revenue momentum ahead of upcoming pipeline readouts. Article Title
• Positive Sentiment: Several analyst notes were constructive, including Guggenheim reiterating a Buy and Citigroup raising its price target, signaling confidence in further upside after the earnings update. Article Title Article Title
• Neutral Sentiment: argenx also released its half-year 2026 financial results and second-quarter business update, which investors are likely parsing for pipeline progress and launch trends. Article Title

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.